Author's response to reviews

Title: Clusterin isoforms expression in thyroid tumour: a potential marker of malignancy?

Authors:

PAOLO FUZIO (pao.lo.fuzio@ba.itb.cnr.it)
ANNA NAPOLI (anna.napoli@uniba.it)
ANNA CIAMPOLILLO (anna.ciampolillo@uniba.it)
SERAFINA LATTARULO (s.lattarulo@virgilio.it)
ANGELA PEZZOLLA (apezzolla@chirges.uniba.it)
NICOLETTA NUZZIELLO (nicoletta.nuzziello@gmail.com)
SABINO LIUNI (sabino.liuni@ba.itb.cnr.it)
FRANCESCO GIORGINO (francesco.giorgino@uniba.it)
EUGENIO MAIORANO (eugenio.maiorano@uniba.it)
ELDA PERLINO (elda.perlino@ba.itb.cnr.it)

Version: 2 Date: 17 September 2014

Author's response to reviews: see over
Bari, 17th September 2014

To Editor-in-Chief:

BMC Cancer
c/o BioMed Central
236 Gray's Inn Road
London WC1X 8HB
United Kingdom

Dear Editors,

We are herewith submitting the manuscript entitled “Clusterin isoforms expression in thyroid tumors: a potential marker of malignancy?” by Paolo Fuzio, Anna Napoli, Anna Ciampolillo, Serafina Lattarulo, Angela Pezzolla, Nicoletta Nuzziello, Sabino Liuni, Francesco Giorgino, Eugenio Maiorano, and Elda Perlino, to be considered for publication in the BMC Cancer, as Research Article.

The study investigates the Clusterin (CLU) in vivo expression at RNA and protein level by qPCR and immunohistochemistry methods. Our model system consists of human neoplastic thyroid tissues in order to assess its possible role as biomarker by using both neoplastic tissues and fine needle aspiration biopsies. Our results suggest for the first time the existence of a complex regulatory mechanism of CLU gene expression during the progression from normal to malignant thyroid cell and a possible alteration of the CLU isoforms ratio, thus providing the first evidence for the potential future use of CLU isoforms as biomarkers for the indeterminate thyroid nodule.

I declare that the material included in the manuscript has not been previously published (except in the form of an abstract or as part of a published lecture or academic thesis) or elsewhere submitted for publication. Moreover, the publication of the data is approved by all authors and explicitly by the responsible authorities where the work was carried out and, if accepted, it will not be published elsewhere in the same form, in English or any other language, without the written consent of the Publisher.

Thank you for your consideration. We look forward to hearing from the Journal soon.

Yours sincerely,
Dr. Elda Perlino
Senior Researcher
Institute of Biomedical Technologies, ITB – CNR, Bari
Via Amendola 122/D - 70126 Bari (Italy)
Tel. +39 80 5929688; Fax. +39 80 5929690; Cell. +39 347 8781806
e_mail: elda.perlino@ba.itb.cnr.it